Prime Capital Investment Advisors LLC Has $1.08 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Prime Capital Investment Advisors LLC lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,654 shares of the biotechnology company’s stock after acquiring an additional 249 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Sarepta Therapeutics were worth $1,081,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Innealta Capital LLC purchased a new position in Sarepta Therapeutics during the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at $43,000. Riggs Asset Managment Co. Inc. lifted its stake in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares in the last quarter. Finally, UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. The trade was a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 3.0 %

Shares of SRPT stock opened at $109.11 on Friday. The stock has a 50 day moving average of $124.21 and a 200-day moving average of $132.49. The firm has a market cap of $10.42 billion, a PE ratio of 87.29 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12 month low of $78.67 and a 12 month high of $173.25.

Analyst Ratings Changes

SRPT has been the topic of a number of research reports. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Evercore ISI lowered their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 21st. One investment analyst has rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.